Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Multiple genomic changes caused by clonal evolution induced by therapeutic pressure and corresponding intratumoral heterogeneity have posed great challenges for personalized therapy against metastatic colorectal cancer (mCRC) in the past decade. Liquid biopsy has emerged as an excellent molecular diagnostic tool for assessing predominant spatial and temporal intratumoral heterogeneity with minimal invasiveness. Previous studies have revealed that genomic alterations in RAS, BRAF, ERBB2, and MET, as well as other cancer-related genes associated with resistance to anti-epidermal growth factor receptor (EGFR) therapy, can be analyzed with high diagnostic accuracy by circulating tumor DNA (ctDNA) analysis. Furthermore, by longitudinally monitoring ctDNAs during anti-EGFR therapy, the emergence of genomic alterations can be detected as acquired resistance mechanisms in specific genes, mainly those associated with the mitogen-activated protein kinase signaling pathway. Analysis of ctDNA can also identify predictive biomarkers to immune checkpoint inhibitors, such as mutations in mismatch repair genes, microsatellite instability-high phenotype, and tumor mutation burden. Some prospective clinical trials evaluating targeted agents for genomic alterations in ctDNA or exploring resistance biomarkers by monitoring of ctDNA are ongoing. To determine the value of ctDNA analysis for decision-making by more accurate molecular marker-based selection of patients and identification of resistance mechanisms to targeted therapies or sensitive biomarkers for immune checkpoint inhibitors, clinical trials must be refined to evaluate the efficacy of study treatment in patients with targetable genomic alterations confirmed by ctDNA analysis, and resistance biomarkers should be explored by monitoring ctDNA in large-scale clinical trials. In the near future, ctDNA analysis will play an important role in precision medicine for mCRC. Implications for Practice: Treatment strategies for metastatic colorectal cancer (mCRC) are determined according to the molecular profile, which is confirmed by analyzing tumor tissue. Analysis of circulating tumor DNA (ctDNA) may overcome the limitations of tissue-based analysis by capturing spatial and temporal intratumoral heterogeneity of mCRC. Clinical trials must be refined to test the value of ctDNA analysis in patient selection and identification of biomarkers. This review describes ctDNA analysis, which will have an important role in precision medicine for mCRC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“CTDNA ANALYSIS FOR IMMUNE CHECKPOINT INHIBITORS IN MCRC The emergence of immune checkpoint inhibitors targeting Cytotoxic T-lymphocyte associated protein-4 and programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) has facilitated breakthrough developments in cancer immunotherapy; however, most patients with mCRC…”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 1×
“Over the last 20 years, the clinical outcome of patients with metastatic colorectal cancer (mCRC) has improved because of the increased number of patients who undergo surgical resection of metastatic lesions and the development of systemic therapies, including targeted agents [1].”
BackgroundSelf-citationOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“Acquired KRAS mutations have been suggested to emerge not only from the selection of pre-existing KRAS mutant subclones but also as a result of ongoing mutagenesis in the cancer during anti-EGFR therapy [17].”
BackgroundThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016 · cited 1×
“Clinical studies have investigated the efficacy of combined HER2-targeted therapies, which showed some clinical benefit [58, 59].”
BackgroundBertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 2×
“Consistent with these findings, the frequency of ERBB2 amplifications increase from approximately 3% in treatment-na€ıve patients to over 10% in patients administered anti-EGFR treatment [56].”
Background(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D. M., Sieber, O., & Desai, J. (2011) · Cancer · doi:10.1002/cncr.26086 · Cited by 797
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695 · cited 1×
“Guardant360, an NGS-based ctDNA analysis method that targets cancer-related genes, was shown to identify CNAs for multiple genes, including ERBB2, EGFR, and MET, with high diagnostic accuracy [62].”
MethodClinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Thierry, A. R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 678
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657 · cited 1×
“MET Amplification MET amplification is also responsible for de novo and acquired resistance to anti-EGFR therapy for mCRC [67].”
BackgroundLeary, R. J., Sausen, M., Kinde, I., Papadopoulos, N., Carpten, J. D., Craig, D., O’Shaughnessy, J., Kinzler, K. W., Parmigiani, G., Vogelstein, B., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004742 · Cited by 635
Tie, J., Kinde, I., Wang, Y., Wong, H. L., Roebert, J., Christie, M., Tacey, M., Wong, R., Singh, M., Karapetis, C. S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv177 · Cited by 635
Sacher, A. G., Paweletz, C., Dahlberg, S. E., Alden, R. S., O’Connell, A., Feeney, N., Mach, S. L., Jänne, P. A., & Oxnard, G. R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0173 · Cited by 571
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513 · cited 1×
“in mCRC, resulting in acquired secondary resistance [3].”
BackgroundMontagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513 · cited 1×
“One study identified a point mutation (S492R) within the EGFR ectodomain (ECD) that arose in a cetuximab-resistant cell line and demonstrated that panitumumab could block EGFR activation in these mutants [50].”
BackgroundTaly, V., Pekin, D., Benhaim, L., Kotsopoulos, S. K., Le Corre, D., Li, X., Atochin, I., Link, D. R., Griffiths, A. D., Pallier, K., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.206359 · Cited by 492
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479
Stintzing, S., Modest, D. P., Rossius, L., Lerch, M. M., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30269-8 · Cited by 420
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., Mussolin, B., Kwak, E. L., Buscarino, M., Lazzari, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1283 · Cited by 405
Heitzer, E., Ulz, P., Belic, J., Gutschi, S., Quehenberger, F., Fischereder, K., Benezeder, T., Auer, M., Pischler, C., Mannweiler, S., et al. (2013) · Genome Medicine · doi:10.1186/gm434 · Cited by 357
Vidal, J., Muinelo, L., Dalmases, A., Jones, F., Edelstein, D., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx125 · Cited by 344
Tabernero, J., Lenz, H.-J., Siena, S., Sobrero, A., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00138-2 · Cited by 328
Self-citationRowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.173 · Cited by 319
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Valtorta, E., Martino, C., Sartore-Bianchi, A., Penaullt-Llorca, F., Viale, G., Risio, M., Rugge, M., Grigioni, W., Bencardino, K., Lonardi, S., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.98 · Cited by 313
Chung, K. Y., Gore, I., Fong, L., Venook, A., Beck, S. B., Dorazio, P., Criscitiello, P. J., Healey, D. I., Huang, B., Gomez-Navarro, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3994 · Cited by 306
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2821 · Cited by 271
Misale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007947 · Cited by 263
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
Bokemeyer, C., Köhne, C.-H., Ciardiello, F., Lenz, H.-J., Heinemann, V., Klinkhardt, U., Beier, F., Duecker, K., van Krieken, J. H., & Tejpar, S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.007 · Cited by 256
Morelli, M. P., Overman, M. J., Dasari, A., Kazmi, S. M. A., Mazard, T., Vilar, E., Morris, V. K., Lee, M. S., Herron, D., Eng, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv005 · Cited by 254
Spindler, K.-L. G., Pallisgaard, N., Vogelius, I., & Jakobsen, A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0564 · Cited by 251
Garlan, F., Laurent-Puig, P., Sefrioui, D., Siauve, N., Didelot, A., Sarafan-Vasseur, N., Michel, P., Perkins, G., Mulot, C., Blons, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3155 · Cited by 250
Paweletz, C. P., Sacher, A. G., Raymond, C. K., Alden, R. S., O'Connell, A., Mach, S. L., Kuang, Y., Gandhi, L., Kirschmeier, P., English, J. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1627-t · Cited by 244
Mouliere, F., El Messaoudi, S., Pang, D., Dritschilo, A., & Thierry, A. R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.02.005 · Cited by 230
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.325 · Cited by 229
Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13665 · Cited by 214
Khagi, Y., Goodman, A. M., Daniels, G. A., Patel, S. P., Sacco, A. G., Randall, J. M., Bazhenova, L. A., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1439 · Cited by 202
Grasselli, J., Elez, E., Caratù, G., Matito, J., Santos, C., Macarulla, T., Vidal, J., Garcia, M., Viéitez, J. M., Paéz, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx112 · Cited by 187
Pietrantonio, F., Vernieri, C., Siravegna, G., Mennitto, A., Berenato, R., Perrone, F., Gloghini, A., Tamborini, E., Lonardi, S., Morano, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1863 · Cited by 182
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181
Normanno, N., Rachiglio, A. M., Lambiase, M., Martinelli, E., Fenizia, F., Esposito, C., Roma, C., Troiani, T., Rizzi, D., Tatangelo, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv176 · Cited by 157
Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution
Uchi, R., Takahashi, Y., Niida, A., Shimamura, T., Hirata, H., Sugimachi, K., Sawada, G., Iwaya, T., Kurashige, J., Shinden, Y., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005778 · Cited by 157
Schmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12023 · Cited by 152
Thierry, A. R., Messaoudi, S. E., Mollévi, C., Raoul, J., Guimbaud, R., Pezet, D., Artru, P., Assénat, E., Borg, C., Mathonnet, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx330 · Cited by 117
DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer
Mamlouk, S., Childs, L. H., Aust, D., Heim, D., Melching, F., Oliveira, C., Wolf, T., Durek, P., Schumacher, D., Bläker, H., et al. (2017) · Nature Communications · doi:10.1038/ncomms14093 · Cited by 110
Leto, S. M., Sassi, F., Catalano, I., Torri, V., Migliardi, G., Zanella, E. R., Throsby, M., Bertotti, A., & Trusolino, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3066 · Cited by 104
Spindler, K. G., Pallisgaard, N., Andersen, R. F., & Jakobsen, A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28863 · Cited by 89
Andreou, A., Kopetz, S., Maru, D. M., Chen, S. S., Zimmitti, G., Brouquet, A., Shindoh, J., Curley, S. A., Garrett, C. R., Overman, M. J., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826b4dcc · Cited by 84
Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1432 · Cited by 77 · cited 1×
“Sym004, a 1:1 mixture of two antibodies against nonoverlapping epitopes of EGFR ECD, has been developed to overcome the resistance to antiEGFR therapy and demonstrated tumor shrinkage in patients whose disease progressed after anti-EGFR therapy, including a patient with EGFR S492R mutation in a phase I trial [52].”
BackgroundRaghav, K., Morris, V., Tang, C., Morelli, P., Amin, H. M., Chen, K., Manyam, G. C., Broom, B., Overman, M. J., Shaw, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10559 · Cited by 77
Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review
Fan, G., Zhang, K., Yang, X., Ding, J., Wang, Z., & Li, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171991 · Cited by 76
Kim, S. T., Banks, K. C., Lee, S.-H., Kim, K., Park, J. O., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Lanman, R. B., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00059 · Cited by 73
Takegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6498 · Cited by 70
Kirkizlar, E., Zimmermann, B., Constantin, T., Swenerton, R., Hoang, B., Wayham, N., Babiarz, J. E., Demko, Z., Pelham, R. J., Kareht, S., et al. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.08.004 · Cited by 48
Patterson, S. D., Peeters, M., Siena, S., Cutsem, E. V., Humblet, Y., Laethem, J. V., André, T., Tian, Y., Sidhu, R., & Oliner, K. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3617 · Cited by 43
Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA
Diaz, L. A., Sausen, M., Fisher, G. A., & Velculescu, V. E. (2013) · Oncotarget · doi:10.18632/oncotarget.1486 · Cited by 39
Hurwitz, H., Raghav, K. P. S., Burris, H. A., Kurzrock, R., Sweeney, C., Meric-Bernstam, F., Vanderwalde, A. M., Spigel, D. R., Bose, R., Fakih, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.676 · Cited by 38
Liquid biopsies to evaluate early therapeutic response in colorectal cancer
Montagut, C. O., Siravegna, G., & Bardelli, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv228 · Cited by 25
Price, T. J., Newhall, K. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. V., Thomas, A., Tjulandin, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.740 · Cited by 15
Yoshino, T., Uetake, H., Tsuchihara, K., Shitara, K., Yamazaki, K., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Kato, T., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.001 · Cited by 15
Self-citationClinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer
Trojan, J., Klein‐Scory, S., Koch, C., Schmiegel, W., & Baraniskin, A. (2017) · Case Reports in Oncological Medicine · doi:10.1155/2017/6139634 · Cited by 13
Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis
Otsuka, K., Satoyoshi, R., Nanjo, H., Miyazawa, H., Abe, Y., Tanaka, M., Yamamoto, Y., & Shibata, H. (2011) · Oncology Letters · doi:10.3892/ol.2011.543 · Cited by 11
Nakamura, Y., Okamoto, W., Sawada, K., Komatsu, Y., Kato, K., Taniguchi, H., Kato, T., Nishina, T., Esaki, T., Nomura, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.137 · Cited by 11
Self-citationBachet, J., Bouché, O., Taı̈eb, J., Dubreuil, O., Garcia‐Larnicol, M., Meurisse, A., Gornet, J., Artru, P., Louafi, S., Soularue, É., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.11509 · Cited by 11
Strickler, J. H., Rushing, C. N., Uronis, H. E., Morse, M. A., Blobe, G. C., Zafar, Y., Hsu, S. D., Arrowood, C., Haley, S. T., Dropkin, E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3548 · Cited by 4
Kim, S. R., Srinivasan, A., Allegra, C. J., Jacobs, S. A., Nagy, R. J., Lanman, R. B., Talasaz, A. H., Gavin, P. G., Pal, R., Lucas, P. C., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-5684 · Cited by 2
Tabernero, J. M., Ciardiello, F., Montagut, C. O., Ding, C., Kopetz, S., Poulsen, T. T., Bardelli, A., Wyrwicz, L. S., Cubillo, A., Santos, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.005 · Cited by 2
Boedigheimer, M. J., Ang, A. L., Price, T. J., Peeters, M., Kim, T. W., Gibbs, P., Thomas, A., Hool, K., & Bach, B. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3523 · Cited by 2
Lee, J. J., Palma, J. F., Yao, L., Lovejoy, A. F., Yaung, S. J., Zhang, D., Wingate-Pearse, N., Yau, M., Williams, C., Pimentel, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e15118 · Cited by 1
Research works printed but not linked: 1
- Corcoran, 2016, Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600Er. g hepateRAFm) metastatic colorectal cancer (mCRC), Ann Oncol, 27, 4550
Cited by
Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1063-5 · Cited by 373
Self-citationNakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y., & Shitara, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00492-2 · Cited by 298
Self-citationNakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231
Self-citationAbbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
“Unlike static tissue assays, liquid biopsy offers minimally invasive sampling, captures tumor heterogeneity from multiple metastatic sites, enables real-time monitoring of molecular evolution, and allows serial assessments throughout therapy [72].”
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“The dynamic nature of these resistance mechanisms, mainly the MET amplification and ECD mutations during treatment, highlights the clinical utility of longitudinal ctDNA monitoring to iden-https tify molecular relapses [33,38].”
Metadata
- Authors
- Nakamura, Y., & Yoshino, T.
- Affiliations
- National Cancer Centre Japan (JP)
- Corresponding author
- Yoshino, Takayuki
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-26
- Volume
- 23
- Issue
- 11
- Pages
- 1310-1318
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC6291328
- OpenAlex
- W2801333751
- Cited by
- 61
- References
- 83
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 16 · 2020: 15 · 2019: 2 · 2018: 1
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- circulating tumor DNA, liquid biopsy, metastatic colorectal cancer, intratumoral heterogeneity, clonal evolution, anti-EGFR therapy resistance, RAS mutations, BRAF mutation, MET amplification, ERBB2, MAPK signaling, immune checkpoint inhibitors, predictive biomarkers, mismatch repair genes, microsatellite instability, tumor mutational burden, precision medicine, longitudinal ctDNA monitoring
- MeSH terms
- Circulating Tumor DNA, Female, Humans, Neoplasm Metastasis, Colorectal Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.